This book aims to provide an update on drugs available for the treatment of type 2 diabetes and where they fit within current treatment algorithms. The limited efficacy and tolerability of older drugs has spurred the development of several new classes of oral and injectable glucose-lowering agents with novel modes of action. These advances reflect progress in our understanding of the pathophysiology of type 2 diabetes. Old and newer drugs are increasingly being used side-by-side.